Suesskind Dan S Form 3/A February 12, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Suesskind Dan S		Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]		
(Last)	(First)	(Middle)	01/01/2018	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., Â 5 BASEL STREET

(Street)

PETACH TIKVA, L3Â 4951033

(City) (State)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned

(Check all applicable)

(give title below) (specify below)

10% Owner

Other

X Director

Officer

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)

SEC 1473 (7-02)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reporting Person

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting

Form filed by More than One

01/02/2018

Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Zip)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration** Date (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

6. Nature of Indirect 4. 5. Conversion Ownership Beneficial or Exercise Form of Ownership Price of Derivative (Instr. 5) Derivative Security:

Edgar Filing: Suesskind Dan S - Form 3/A

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Put Option (Obligation to buy)	04/04/2017	01/19/2018	Ordinary Shares (1)	19,700	\$ 25	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Suesskind Dan S C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA, L3 4951033	ÂX	Â	Â	Â
Signatures				
/s/ Dov Bergwerk, as attorney-in-fact for Dan S. Suesskind		02/12/2018		
**Signature of Reporting Person		Date		
Explanation of Responses:				

nesponses.

If the form is filed by more than one reporting person, see Instruction 5(b)(v). *

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (1)

Â

Remarks:

The Form 3 of the Reporting Person originally filed on January 2, 2018 inadvertently omitted theÂ

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.